UI Hospitals and Clinics
Randomized, Double-blind, Placebo-controlled Phase 3 Study of Ibrutinib, a Bruton's Tyrosine Kinase (BTK) Inhibitor, in Combination with Bendamustine and Rituximab (BR) in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Participants in this study have been diagnosed with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL). There are two treatment groups, one will receive the study drug called ibrutinib and the second group will receive a placebo. The purpose of the study is to assess the effects (both good and bad) of ibrutinib in patients with CLL or SLL and whether the CLL or SLL responds to this treatment.
Mary Schall, 319-356-3516
We welcome your feedback! Please help us improve your experience on our website by completing a brief survey.